Document:

EX-10.15

 Exhibit 10.15 

APPLIED MOLECULAR TRANSPORT, INC. 

SENIOR EXECUTIVE CHANGE IN CONTROL AND SEVERANCE POLICY 

(Adopted on June 1, 2020) 
 This Senior
Executive Change in Control and Severance Policy (the “Policy”) is designed to provide certain protections to a select group of designated key employees of Applied Molecular Transport, Inc. (“AMT” or the
“Company”) or any of its subsidiaries if their employment is involuntarily terminated under the circumstances described in this Policy. The Policy is designed to be an “employee welfare benefit plan” (as defined in
Section 3(1) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”)), and this document is both the formal plan document and the required summary plan description for the Policy. 

 

	1.	 Eligible Employee: An individual is only eligible for protection under this Policy if he or she is an
Eligible Employee and complies with its terms. An “Eligible Employee” is an employee of the Company or any subsidiary of the Company who has (a) been designated by the Compensation Committee of the Board (the
“Compensation Committee”) as eligible to participate in the Policy, whether individually or by position or category of position and (b) executed a participation agreement in the form attached hereto as Exhibit A (a
“Participation Agreement”). Failure to comply with the terms of an individual’s Participation Agreement will result in that individual not being an Eligible Employee. 

 

	2.	 Policy Benefits: An Eligible Employee will be eligible to receive the payments and benefits under
this Policy and his or her Participation Agreement upon his or her Qualified Termination. The amount and terms of any Equity Vesting, Salary Severance, Bonus Severance, and COBRA Benefit that an Eligible Employee may receive upon his or her
Qualified Termination will be set forth in his or her Participation Agreement. All benefits under this Policy will be subject to the Eligible Employee’s compliance with the Release Requirement and any timing modifications required to avoid
adverse taxation under Section 409A. 

  

	3.	 Equity Vesting: On a Qualified Termination, the applicable percentage (set forth in an Eligible
Employee’s Participation Agreement) of the then-unvested shares subject to each of the Eligible Employee’s then-outstanding time-based equity awards will immediately vest and, in the case of options and stock appreciation rights, will
become exercisable (for avoidance of doubt, no more than 100% of the shares subject to the outstanding portion of a time-based equity award may vest and become exercisable pursuant to this provision). Any restricted stock units or similar full value
awards that vest under this paragraph will be settled on the 61st day following the Eligible Employee’s Qualified Termination. For the avoidance of doubt, if an Eligible Employee’s
Qualified Termination occurs prior to a Change in Control, then any unvested portion of the Eligible Employee’s outstanding time-based equity awards will remain outstanding for 3 months so that any additional benefits due on a Qualified
Termination can be provided if a Change in Control occurs within 3 months following the Qualified Termination (provided that in no event will the terminated Eligible Employee’s stock options or similar equity awards remain outstanding beyond
the equity award’s maximum term to expiration). If no Change in Control occurs within 3 months after a Qualified Termination, any unvested portion of the Eligible Employee’s equity awards automatically will be forfeited permanently without
having vested. Any accelerated vesting of an Eligible Employee’s outstanding performance-based equity awards upon a Qualified Termination will be determined by the terms of the award agreements for such equity awards. 

In addition, in the event of a Change in Control where the acquiror or successor corporation does not assume or replace or substitute with an
equivalent award any of the Eligible Employee’s then-unvested time-based equity awards, 100% of then-unvested shares subject to each of the Eligible Employee’s then-outstanding time-based equity awards will immediately vest and, in the
case of options and stock appreciation rights, will become exercisable (for avoidance of doubt, no more than 100% of the shares subject to the outstanding portion of a time-based equity award may vest and become exercisable pursuant to this
provision). 

	4.	 Salary Severance: On a Qualified Termination, an Eligible Employee will be eligible to receive salary
severance payment(s) equal to the applicable percentage (set forth in his or her Participation Agreement) of his or her Base Salary. The Eligible Employee’s salary severance payment(s) will be paid in cash at the time(s) specified in his or her
Participation Agreement. 

  

	5.	 Bonus Severance: To the extent specified in his or her Participation Agreement, on a Qualified
Termination, an Eligible Employee will be eligible to receive bonus severance payment(s) with respect to the Eligible Employee’s annual bonus. If applicable, the Eligible Employee’s bonus severance payment(s) will be paid in cash at the
time(s) specified in his or her Participation Agreement. 

  

	6.	 COBRA Benefit: Upon a Qualified Termination, if an Eligible Employee makes a valid election under COBRA
to continue his or her health coverage, the Company will pay or reimburse the Eligible Employee for the cost of such continuation coverage for the Eligible Employee and any eligible dependents that were covered under the Company’s health care
plans immediately prior to the date of his or her Qualified Termination until the earliest of (a) the end of the period applicable to such Eligible Employee as specified in the Severance Benefits Tables above, (b) the date upon which the
Eligible Employee and/or the Eligible Employee’s eligible dependents become covered under similar plans or (c) the date upon which the Eligible Employee ceases to be eligible for coverage under COBRA (the “COBRA Coverage”).
Notwithstanding the preceding, if the Company determines in its sole discretion that it cannot provide the COBRA Coverage without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service
Act), the Company will instead provide the Eligible Employee a taxable lump-sum payment in an amount equal to the number of months of COBRA Coverage applicable to such Eligible Employee as specified in the
Severance Benefits Table above multiplied by the monthly COBRA premium that the Eligible Employee would be required to pay to continue his or her group health coverage in effect on the date of his or her Qualified Termination, based on the premium
for the first month of COBRA coverage (whichever of such taxable payments or the COBRA Coverage, the “COBRA Benefit”). If the Company provides for a taxable cash payment in lieu of the COBRA Coverage, then such cash payment will be made
regardless of whether the Eligible Employee elects COBRA continuation coverage and such payment will be made in full on the 61st day following the Eligible Employee’s Qualified Termination.  

 

	7.	 Death of Eligible Employee: If the Eligible Employee dies after a Qualified Termination and before all
payments or benefits he or she is entitled to receive under this Policy have been paid, then any such unpaid Salary Severance, Bonus Severance, COBRA Severance or Equity Vesting will be paid to his or her designated beneficiary, if living, or
otherwise to his or her personal representative in a lump-sum payment as soon as possible following his or her death. 

  

	8.	 Recoupment: If the Company discovers after the Eligible Employee’s receipt of payments or benefits
under this Policy that grounds for the termination of the Eligible Employee’s employment for Cause existed, then the Eligible Employee will not receive any further payments or benefits under this Policy and, to the extent permitted under
applicable laws, will be required to repay to the Company any payments or benefits he or she received under the Policy (and any financial gain derived from such payments or benefits). 

	9.	 Release: The Eligible Employee’s receipt of any severance payments or benefits upon his or her
Qualified Termination under this Policy is subject to the Eligible Employee signing and not revoking the Company’s then-standard separation agreement and release of claims (which may include an agreement not to disparage the Company, non-solicit provisions, and other standard terms and conditions) (the “Release” and such requirement, the “Release Requirement”), which must become effective and irrevocable no
later than the 60th day following the Eligible Employee’s Qualified Termination (the “Release Deadline”). If the Release does not become effective and irrevocable by the
Release Deadline, the Eligible Employee will forfeit any right to severance payments or benefits under this Policy. In no event will severance payments or benefits under the Policy be paid or provided until the Release actually becomes effective and
irrevocable. Notwithstanding any other payment schedule set forth in this Policy or the Eligible Employee’s Participation Agreement, none of the severance payments and benefits payable upon such Eligible Employee’s Qualified Termination
under this Policy will be paid or otherwise provided prior to the 60th day following the Eligible Employee’s Qualified Termination. Except as otherwise set forth in an Eligible
Employee’s Participation Agreement or to the extent that payments are delayed under the paragraph below entitled “Section 409A,” on the first regular payroll pay day following the 60th day following the
Eligible Employee’s Qualified Termination, the Company will pay or provide the Eligible Employee the severance payments and benefits that the Eligible Employee would otherwise have received under this Policy on or prior to such date, with the
balance of such severance payments and benefits being paid or provided as originally scheduled. 

  

	10.	 Section 409A: The Company intends that all payments and benefits provided under this
Policy or otherwise are exempt from, or comply with, the requirements of Section 409A of the Code and any guidance promulgated thereunder (collectively, “Section 409A”) so that none of the payments or
benefits will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted in accordance with this intent. No payment or benefits to be paid to an Eligible Employee, if any, under this Policy or
otherwise, when considered together with any other severance payments or separation benefits that are considered deferred compensation under Section 409A (together, the “Deferred Payments”) will be paid or otherwise provided
until such Eligible Employee has a “separation from service” within the meaning of Section 409A. If, at the time of the Eligible Employee’s termination of employment, the Eligible Employee is a “specified employee”
within the meaning of Section 409A, then the payment of the Deferred Payments will be delayed to the extent necessary to avoid the imposition of the additional tax imposed under Section 409A, which generally means that the Eligible
Employee will receive payment on the first payroll date that occurs on or after the date that is 6 months and 1 day following his or her termination of employment. The Company reserves the right to amend the Policy as it deems necessary or
advisable, in its sole discretion and without the consent of any Eligible Employee or any other individual, to comply with any provision required to avoid the imposition of the additional tax imposed under Section 409A or to otherwise avoid
income recognition under Section 409A prior to the actual payment of any benefits or imposition of any additional tax. Each payment, installment, and benefit payable under this Policy is a separate payment for purposes of U.S. Treasury
Regulation Section 1.409A-2(b)(2). In no event will the Company reimburse any Eligible Employee for any taxes that may be imposed on him, including as a result of Section 409A. 

 

	11.	 Parachute Payments: 

 

	 	a.	 Reduction of Severance Benefits. Notwithstanding anything set forth herein to the contrary, if any
payment or benefit that an Eligible Employee would receive from the Company or any other party whether in connection with the provisions herein or otherwise (the “Payment”) would (a) constitute a “parachute payment”
within the meaning of Section 280G of the Code, and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment will be equal to the Best Results
Amount. The “Best Results Amount” will be either (x) the full amount of such Payment or (y) such lesser amount as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing
amounts, 

	 	
taking into account the applicable federal, state and local employment taxes, income taxes and the Excise Tax, results in the Eligible Employee’s receipt, on an after-tax basis, of the greater amount notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting parachute payments is necessary so
that the Payment equals the Best Results Amount, reduction will occur in the following order: (i) cancellation of awards granted “contingent on a change in ownership or control” (within the meaning of Section 280G); (ii) a pro
rata reduction of (A) cash payments that are subject to Section 409A as deferred compensation and (B) cash payments not subject to Section 409A of the Code; (iii) a pro rata reduction of (A) employee benefits that are
subject to Section 409A as deferred compensation and (B) employee benefits not subject to Section 409A; and (iv) a pro rata cancellation of (A) accelerated vesting equity awards that are subject to Section 409A as
deferred compensation and (B) equity awards not subject to Section 409A. In the event that acceleration of vesting of equity awards is to be cancelled, such acceleration of vesting will be cancelled in the reverse order of the date of
grant of a Participant’s equity awards. 

  

	 	b.	 Determination of Excise Tax Liability. The Company will select a professional services firm to make all
of the determinations required to be made under these paragraphs relating to parachute payments. The Company will request that firm provide detailed supporting calculations both to the Company and the Eligible Employee prior to the date on which the
event that triggers the Payment occurs if administratively feasible, or subsequent to such date if events occur that result in parachute payments to the Eligible Employee at that time. For purposes of making the calculations required under these
paragraphs relating to parachute payments, the firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith determinations concerning the application of the Code. The Company and the
Eligible Employee will furnish to the firm such information and documents as the firm may reasonably request in order to make a determination under these paragraphs relating to parachute payments. The Company will bear all costs the firm may
reasonably incur in connection with any calculations contemplated by these paragraphs relating to parachute payments. Any such determination by the firm will be binding upon the Company and the Eligible Employee, and the Company will have no
liability to the Eligible Employee for the determinations of the firm. 

  

	12.	 Administration: The Policy will be administered by the Company, acting through the Compensation
Committee or another duly constituted committee of members of the Board or its delegate, but only to the extent of such delegation of authority or responsibility (in each case, an “Administrator”). The Administrator will have full
discretion to administer and interpret the Policy. Any decision made or other action taken by the Administrator with respect to the Policy and any interpretation by the Administrator of any term or condition of the Policy, or any related document,
will be conclusive and binding on all persons and be given the maximum possible deference allowed by law. The Administrator is the “named fiduciary” and “plan administrator” of the Policy for purposes of ERISA and will be subject
to the fiduciary standards of ERISA when acting in such capacity. The Administrator may, in its sole discretion and on such terms and conditions as it may provide, delegate in writing to one or more officers of the Company all or any portion of its
authority or responsibility with respect to the Policy. 

  

	13.	 Attorneys’ Fees: The Company and each Eligible Employee will bear their own attorneys’ fees
incurred in connection with any disputes between them. 

  

	14.	 Exclusive Benefits: Except as may be set forth in an Eligible Employee’s Participation Agreement,
this Policy is intended to be the only agreement between the Eligible Employee and the Company regarding any change in control or severance payments or benefits to be paid to the Eligible Employee on account of a termination of employment whether
unrelated to, concurrent with, or following, a Change in Control. 

	 	
Accordingly, by executing a Participation Agreement, an Eligible Employee hereby forfeits and waives any rights to any severance or change in control benefits set forth in any employment
agreement, offer letter, and/or equity award agreement, except as set forth in this Policy and in the Eligible Employee’s Participation Agreement. 

  

	15.	 Tax Obligations: All payments and benefits under this Policy will be paid less applicable withholding
taxes. The Company is authorized to withhold from any payments or benefits all U.S. federal, state, local and/or non-U.S. taxes required to be withheld therefrom and any other required payroll deductions. The
Company will not pay any Eligible Employee’s taxes arising from or relating to any payments or benefits under this Policy. The Eligible Employee will be solely responsible for the payment of all personal tax liability that is incurred as a
result of the payments and benefits received under this Policy, and the Eligible Employee will not be reimbursed by the Company for any such payments. 

  

	16.	 Term: Subject to the terms of this paragraph, this Policy will have a term of 3 years commencing on the
Effective Date (the “Term”) unless the Board or the Compensation Committee, as applicable, decides to sooner terminate this Policy in accordance with the terms of this Policy or the affected Eligible Employee consents to an earlier
termination. Any termination of this Policy by the Board or the Compensation Committee, as applicable, must be in writing and will be taken in a non-fiduciary capacity. Neither the lapse of this Policy by its
terms nor the termination of this Policy by the Company will by itself constitute termination of employment or grounds for a Constructive Termination. Further, if a Change in Control occurs when there are fewer than 6 months remaining during the
Term, the Term will extend automatically through the date that is 18 months following the date of the Change in Control (unless the affected Eligible Employee consents to an earlier termination). Notwithstanding the foregoing, if during the Term, an
initial occurrence of an act or omission by the company constituting the grounds for “Constructive Termination” in accordance with the definition herein has occurred (the “Initial Grounds”), and the expiration date
of the Cure Period (as such defined herein) with respect to such Initial Grounds could occur following the expiration of the Term, the Term will extend automatically through the date that is 30 days following the expiration of the Cure Period, but
such extension of the Term will only apply with respect to the Initial Grounds. 

  

	17.	 Amendment: Subject to this Section 17, the Board or the Compensation Committee may amend the Policy
in writing at any time, without advance notice to any Eligible Employee or other individual and without regard to the effect of the amendment on any Eligible Employee or on any other individual. Any amendment to the Plan that (a) causes an
individual to cease to be a Eligible Employee, or (b) reduces or alters to the detriment of the Eligible Employee the Severance Benefits potentially payable to the Eligible Employee (including, without limitation, imposing additional conditions
or modifying the timing of payment) (an amendment described in clause (a) and/or clause (b) being an “adverse amendment or termination”), will be effective only if it is approved by the Company and communicated to the affected
individual(s) in writing more than 18 months before the effective date of the adverse amendment or termination. Once a Participant has incurred a Qualified Termination, no amendment or termination of the Plan may, without that Participant’s
written consent, reduce or alter to the detriment of the Participant, the Severance Benefits payable to the Participant. In addition and notwithstanding the preceding, beginning on the date that the Change in Control Period begins, the Company may
not, without a Participant’s written consent, amend or terminate the Plan in any way, nor take any other action under the Plan, which (i) prevents that Eligible Employee from becoming eligible for Severance Benefits, or (ii) reduces
or alters to the detriment of the Eligible Employee the Severance Benefits payable, or potentially payable, to the Eligible Employee (including, without limitation, imposing additional conditions). Any action of the Company in amending or
terminating the Plan will be taken in a non-fiduciary capacity. 

	18.	 Claims Procedure: Any Eligible Employee who believes he or she is entitled to any payment under the
Policy may submit a claim in writing to the Administrator. If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Policy on
which the denial is based. The notice will also describe any additional information needed to support the claim and the Policy’s procedures for appealing the denial. The denial notice will be provided within 90 days after the claim is received.
If special circumstances require an extension of time (up to 90 days), written notice of the extension will be given within the initial 90-day period. This notice of extension will indicate the special
circumstances requiring the extension of time and the date by which the Administrator expects to render its decision on the claim. 

  

	19.	 Appeal Procedure: If the claimant’s claim is denied, the claimant (or his or her authorized
representative) may apply in writing to the Administrator for a review of the decision denying the claim. Review must be requested within 60 days following the date the claimant received the written notice of their claim denial or else the claimant
loses the right to review. The claimant (or representative) then has the right to review and obtain copies of all documents and other information relevant to the claim, upon request and at no charge, and to submit issues and comments in writing. The
Administrator will provide written notice of the decision on review within 60 days after it receives a review request. If additional time (up to 60 days) is needed to review the request, the claimant (or representative) will be given written notice
of the reason for the delay. This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Administrator expects to render its decision. If the claim is denied (in full or in part), the
claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Policy on which the denial is based. The notice will also include a statement that the claimant will be provided, upon
request and free of charge, reasonable access to, and copies of, all documents and other information relevant to the claim and a statement regarding the claimant’s right to bring an action under Section 502(a) of ERISA.

  

	20.	 Successors: Any successor to the Company of all or substantially all of the Company’s business
and/or assets (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or other transaction) must assume the obligations under the Policy and agree expressly to perform the obligations under the Policy in the same
manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under the Policy, the term “Company” will include any successor to the Company’s business
and/or assets which becomes bound by the terms of the Policy by operation of law, or otherwise. 

  

	21.	 Applicable Law: The provisions of the Policy will be construed, administered, and enforced in accordance
with ERISA and, to the extent applicable, the internal substantive laws of the state of California (but not its conflict of laws provisions). 

  

	22.	 Definitions: Unless otherwise defined in an Eligible Employee’s Participation Agreement, the
following terms will have the following meanings for purposes of this Policy and the Eligible Employee’s Participation Agreement: 

  

	 	a.	 “Base Salary” means the Eligible Employee’s annual base salary as in effect immediately
prior to his or her Qualified Termination (or if the termination is due to a resignation in a Constructive Termination based on a material reduction in base salary, then the Eligible Employee’s annual base salary in effect immediately prior to
such reduction) or, if the Eligible Employee’s Qualified Termination occurs following the Change in Control, at the level in effect immediately prior to the Change in Control if the pre-Change in Control
amount is greater. 

  

	 	b.	 “Board” means the Board of Directors of the Company. 

	 	c.	 “Cause” means the occurrence of any of the following: (a) the Eligible Employee’s
engaging in illegal conduct that is determined by the Committee to be materially injurious to the Company or any of its subsidiaries; (b) the Eligible Employee’s violation of a U.S. federal or state law or regulation or a law or regulation
of any other jurisdiction applicable to the Company’s business which violation was or is reasonably likely to be injurious to the Company or any of its subsidiaries; (c) the Eligible Employee’s material breach of the terms of any
confidentiality agreement or invention assignment agreement between the Eligible Employee and the Company or any of its subsidiaries, as determined in good faith by the Committee; (d) the Eligible Employee’s conviction for, or entry of a
plea of nolo contendere to, a felony involving any act of moral turpitude, dishonesty, fraud against, or the misappropriation of material property belonging to, the Company or any of its subsidiaries; (e) the Eligible Employee’s
gross negligence or willful misconduct in the performance of his or her duties to the Company that has resulted or is likely to result in material damage to the Company, or continued and willful violations of his or her obligations to the Company as
an employee of the Company or any of its subsidiaries, as determined in good faith by the Committee, and the Eligible Employee’s failure to cure such violations within the thirty (30)-day period following
written notice from the Committee; (f) any breach by the Eligible Employee of any material provision of the terms of his or her employment or engagement by the Company or any of its subsidiaries that is determined by the Committee to be
materially injurious to the Company or any of its subsidiaries. 

  

	 	d.	 “Change in Control” has the meaning set forth in the Company’s 2020 Equity Incentive
Plan, as hereinafter may be amended, or if such plan is not in effect at a relevant time, the Company’s then effective equity incentive plan. 

  

	 	e.	 “Change in Control Period” will mean the period beginning on a Change in Control and ending 12
months following a Change in Control. 

  

	 	f.	 “COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985.

  

	 	g.	 “Code” means the Internal Revenue Code of 1986. 

 

	 	h.	 “Constructive Termination” means the Eligible Employee’s termination of his or her
employment with the Company (or any of its subsidiaries) in accordance with the next sentence after the occurrence of one or more of the following events without the Eligible Employee’s consent: (a) a material reduction in the Eligible
Employee’s authority, duties, or responsibilities with the Company or a subsidiary of the Company in effect immediately prior to such reduction, unless the Eligible Employee is provided with reasonably comparable authority, duties, or
responsibilities; (b) a material change in the geographic location at which the Eligible Employee must be principally located for employment, provided that a change in office location of greater than forty (40) miles from the Eligible
Employee’s home will be such a material change in geographic location; (c) a material reduction by the Company or a subsidiary of the Company in the Eligible Employee’s total target cash compensation as in effect immediately prior to
such reduction other than in connection with a general reduction of total target cash compensation at the Company or its subsidiaries of individuals having a similar position or title; or (d) any material breach by the Company or a subsidiary
of the Company of the agreement under which the Eligible Employee provides services to the Company or such subsidiary. In order for the Eligible Employee’s termination of his or her employment to be for Good Reason, the Eligible Employee must
not terminate employment with the Company without first providing the Company with written notice of the acts or omissions constituting the grounds for “Good Reason” within 90 days of the initial existence of the grounds for “Good
Reason” and a cure period of 30 days following the date of written notice (the “Cure Period”), such grounds must not have been cured during such time, and the Eligible Employee must terminate his or her employment within 60 days
following the Cure Period. 

	 	i.	 “Disability” means the total and permanent disability as defined in Section 22(e)(3) of
the Code unless the Company maintains a long-term disability plan at the time of the Eligible Employee’s termination, in which case, the determination of disability under such plan also will be considered “Disability” for purposes of
this Policy. 

  

	 	j.	 “Effective Date” means the date this Policy was approved by the Board. 

 

	 	k.	 “Exchange Act” means the Securities and Exchange Act of 1934. 

 

	 	l.	 “Qualified Termination” has the meaning set forth in the Eligible Employee’s
Participation Agreement. 

  

	 	m.	 “Severance Benefits” means Salary Severance, Bonus Severance, COBRA Severance or Equity
Vesting. 

 Additional Information: 
  

			
	Plan Name:	  	Applied Molecular Transport, Inc. Senior Executive Change in Control and Severance Policy
		
	Plan Sponsor:	  	Applied Molecular Transport, Inc.
		  	1 Tower Place, Suite 850
		  	South San Francisco, CA 94080
		
	Identification Numbers:	  	
		
	Plan Year:	  	Company’s Fiscal Year
		
	Plan Administrator:	  	Applied Molecular Transport, Inc.
		  	Attention: Administrator of the Applied Molecular Transport,
		  	Inc. Senior Executive Change in Control and Severance Policy
		  	1 Tower Place, Suite 850
		  	South San Francisco, CA 94080
		
	Agent for Service of Legal Process:	  	Applied Molecular Transport, Inc.
		  	1 Tower Place, Suite 850
		  	South San Francisco, CA 94080
		
		  	Service of process may also be made upon the Plan Administrator.
		
	Type of Plan	  	Severance Plan/Employee Welfare Benefit Plan
		
	Plan Costs	  	The cost of the Policy is paid by the Company.

 Statement of ERISA Rights: 

Eligible Employees have certain rights and protections under ERISA: 

They may examine (without charge) all Policy documents, including any amendments and copies of all documents filed with the U.S. Department of Labor, such as
the Policy’s annual report (Internal Revenue Service Form 5500). These documents are available for review in the Company’s Human Resources Department. 

They may obtain copies of all Policy documents and other Policy information upon written request to the Plan Administrator. A reasonable charge may be made
for such copies. 
 In addition to creating rights for Eligible Employees, ERISA imposes duties upon the people who are responsible for the operation of the
Policy. The people who operate the Policy (called “fiduciaries”) have a duty to do so prudently and in the interests of Eligible Employees. No one, including the Company or any other person, may fire or otherwise discriminate against an
Eligible Employee in any way to prevent them from obtaining a benefit under the Policy or exercising rights under ERISA. If an Eligible Employee’s claim for a severance benefit is denied, in whole or in part, they must receive a written
explanation of the reason for the denial. An Eligible Employee has the right to have the denial of their claim reviewed. (The claim review procedure is explained above.) 

Under ERISA, there are steps Eligible Employees can take to enforce the above rights. For instance, if an Eligible Employee requests materials and does not
receive them within 30 days, they may file suit in a federal court. In such a case, the court may require the Administrator to provide the materials and to pay the Eligible Employee up to $110 a day until they receive the materials, unless the
materials were not sent because of reasons beyond the control of the Plan Administrator. If an Eligible Employee has a claim which is denied or ignored, in whole or in part, he or she may file suit in a state or federal court. If it should happen
that an Eligible Employee is discriminated against for asserting their rights, he or she may seek assistance from the U.S. Department of Labor, or may file suit in a federal court. 

In any case, the court will decide who will pay court costs and legal fees. If the Eligible Employee is successful, the court may order the person sued to pay
these costs and fees. If the Eligible Employee loses, the court may order the Eligible Employee to pay these costs and fees, for example, if it finds that the claim is frivolous. 

If an Eligible Employee has any questions regarding the Policy, please contact the Plan Administrator. If an Eligible Employee has any questions about this
statement or about their rights under ERISA, they may contact the nearest area office of the Employee Benefits Security Administration (formerly the Pension and Welfare Benefits Administration), U.S. Department of Labor, listed in the telephone
directory, or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W. Washington, D.C. 20210. An Eligible Employee may also obtain certain publications
about their rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration. 

 C-Suite Executives 

EXHIBIT A 

Senior Executive Change in Control and Severance Policy 

Participation Agreement 

This Participation Agreement (“Agreement”) is made and entered into by and between [●] on the one hand, and Applied
Molecular Transport, Inc. (the “Company”) on the other. 
 You have been designated as eligible to participate in the
Policy, a copy of which is attached hereto, pursuant to which you are eligible to receive the following severance payments and benefits upon a Qualified Termination, subject to the terms and conditions of the Policy. 

Qualified Termination means a termination of your employment by the Company (or any of its subsidiaries) other than for Cause, death, or Disability or
by you due to a Constructive Termination, in either case (i) during the Change in Control Period (a “CIC Qualified Termination”) or (ii) outside the Change in Control Period (a
“Non-CIC Qualified Termination”). 
 Non-CIC Qualified
Termination 
  

	 	•	 	 Equity Vesting: None. 

 

	 	•	 	 Salary Severance: Your percentage of Base Salary will be 100%, payable in a
lump-sum on the 61st day following your Qualified Termination. 

  

	 	•	 	 COBRA Severance: The Company will pay for your COBRA continuation coverage (or COBRA Replacement Payments,
as applicable) for up to 12 months. 

 CIC Qualified Termination 

 

	 	•	 	 Equity Vesting: Your equity vesting benefit will be 100% (time-based awards). 

 

	 	•	 	 Salary Severance: Your percentage of Base Salary will be 100%, payable in a
lump-sum on the 61st day following your Qualified Termination. 

  

	 	•	 	 Bonus Severance: You will receive a lump-sum payment equal to 100%
of your target annual bonus as in effect for the fiscal year in which your Qualified Termination occurs, payable on the 61st day following your Qualified Termination. 

 

	 	•	 	 COBRA Severance: The Company will pay for your COBRA continuation coverage (or COBRA Replacement Payments,
as applicable) for up to 12 months. 

 Other Provisions 

Except as set forth in this paragraph, you agree that the Policy and the Agreement constitute the entire agreement of the parties hereto and supersede in their
entirety all prior representations, understandings, undertakings or agreements (whether oral or written and whether expressed or implied) of the parties, and will specifically supersede any prior severance and/or change in control policy and any
severance and/or change in control provisions of any offer letter, employment agreement, or equity award agreement entered into between you and the Company. For the avoidance of doubt, any vesting acceleration in your existing employment agreement
and/or equity award agreement with the Company occurring upon certain qualifying terminations of employment occurring in connection with or following a “change in control” (or similar term as defined in the applicable agreement) will be
superseded by the Policy and this Agreement. 

 This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument. 
 By its signature below, each of the parties signifies its acceptance of the terms
of this Agreement, in the case of the Company by its duly authorized officer effective as of the last date set forth below. 
  

											
	APPLIED MOLECULAR TRANSPORT, INC.	 		 		 	 ELIGIBLE EMPLOYEE

						
	 By:
	 	  
	 		 		 	 Signature:
	 	  

						
	 Date:
	 	  
	 		 		 	 Date:
	 	  

 VPs 

EXHIBIT A 

Senior Executive Change in Control and Severance Policy 

Participation Agreement 

This Participation Agreement (“Agreement”) is made and entered into by and between [●] on the one hand, and
Applied Molecular Transport, Inc. (the “Company”) on the other. 
 You have been designated as eligible to participate in
the Policy, a copy of which is attached hereto, pursuant to which you are eligible to receive the following severance payments and benefits upon a Qualified Termination, subject to the terms and conditions of the Policy. 

Qualified Termination means either (i) a termination of your employment by the Company (or any of its subsidiaries) other than for Cause, death,
or Disability or by you due to a Constructive Termination, in either case, during the Change in Control Period (a “CIC Qualified Termination”) or (ii) a termination of your employment by the Company (or any of its subsidiaries)
other than for Cause, death, or Disability outside the Change in Control Period (a “Non-CIC Qualified Termination”). 

Non-CIC Qualified Termination 
  

	 	•	 	 Equity Vesting: None. 

 

	 	•	 	 Salary Severance: Your percentage of Base Salary will be 50%, payable in a
lump-sum on the 61st day following your Qualified Termination. 

  

	 	•	 	 COBRA Severance: The Company will pay for your COBRA continuation coverage (or COBRA Replacement Payments,
as applicable) for up to 6 months. 

 CIC Qualified Termination 

 

	 	•	 	 Equity Vesting: Your equity vesting benefit will be 100% (time-based awards). 

 

	 	•	 	 Salary Severance: Your percentage of Base Salary will be 100%, payable in a
lump-sum on the 61st day following your Qualified Termination. 

  

	 	•	 	 Bonus Severance: You will receive a lump-sum payment equal to 100%
of your target annual bonus as in effect for the fiscal year in which your Qualified Termination occurs payable on the 61st day following your Qualified Termination. 

 

	 	•	 	 COBRA Severance: The Company will pay for your COBRA continuation coverage (or COBRA Replacement Payments,
as applicable) for up to 12 months. 

 Other Provisions 

Except as set forth in this paragraph, you agree that the Policy and the Agreement constitute the entire agreement of the parties hereto and supersede in their
entirety all prior representations, understandings, undertakings or agreements (whether oral or written and whether expressed or implied) of the parties, and will specifically supersede any prior severance and/or change in control policy and any
severance and/or change in control provisions of any offer letter, employment agreement, or equity award agreement entered into between you and the Company. For the avoidance of doubt, any vesting acceleration in your existing employment agreement
and/or equity award agreement with the Company occurring upon certain qualifying terminations of employment occurring in connection with or following a “change in control” (or similar term as defined in the applicable agreement) will be
superseded by the Policy and this Agreement. 

 This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument. 
 By its signature below, each of the parties signifies its acceptance of the terms
of this Agreement, in the case of the Company by its duly authorized officer effective as of the last date set forth below. 
  

											
	APPLIED MOLECULAR TRANSPORT, INC.	 		 		 	 ELIGIBLE EMPLOYEE

						
	 By:
	 	  
	 		 		 	 Signature:
	 	  

						
	 Date:
	 	  
	 		 		 	 Date:ccc_Ex10_5

		
			Exhibit 10.5
		

		
			CLARIVATE PLC
		

		
			Friars House
		

		
			160 Blackfriars Road
		

		
			London SE1 8EZ United Kingdom
		

		
			June 1, 2020
		

		
			Camelot Holdings (Jersey) Limited
Friars House
160 Blackfriars Road
London SE1 8EZ United Kingdom
		

		
			Re:      Amendment to Sponsor Agreement (this “Agreement”)
		

		
			Ladies and Gentlemen:
		

		
			Reference is made to the Sponsor Agreement, dated January 14, 2019 (as amended, the “Sponsor Agreement”) by and among Churchill Capital Corp, a Delaware corporation (“Churchill”), Camelot Holdings (Jersey) Limited, a private limited company organized under the laws of the Island of Jersey (the “Company”), Clarivate Plc, a public limited company organized under the laws of the Island of Jersey (“Holdings”), Churchill Sponsor LLC, a Delaware limited liability company (“Sponsor”),  Garden State Capital Partners LLC, a Delaware limited liability company, and the Founders (as defined therein). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Sponsor Agreement.
		

		
			WHEREAS, paragraph 5(b) of the Sponsor Agreement provides terms with respect to the allotment and issuance by Holdings of 7,000,000 newly-issued ordinary shares of Holdings (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like, called sweetener shares in the Sponsor Agreement but henceforth shall be called the “Merger Shares”);
		

		
			WHEREAS, the board of directors of the Company has determined to waive the stock price level performance condition described in Section 5(b) of the Sponsor Agreement with respect to the Merger Shares and that the Merger Shares shall be issued on or prior to December 31, 2020 (but not during the continuance of any ordinary share lock-up imposed by underwriters in connection with a Holdings offering applicable to recipients of Merger Shares (as defined below), unless such a lock-up is in existence on December 31, 2020); and
		

		
			WHEREAS, Holdings may, subject to the terms of that certain Amended and Restated Registration Rights Agreement dated May 13, 2019, file with the United States Securities and Exchange Commission from time to time one or more registration statements to register the offer and sale of ordinary shares of Holdings on its own behalf and/or on behalf of certain selling shareholders  (any such offering, a  “Registered Offering”).
		

		
			 
		

		
			

		 

		

			 

		

		

		
			NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed that:
		

		
			Section 1.  Amendments.  Effective as of the date hereof,  the Sponsor Agreement is amended pursuant to Paragraph 12 thereof as follows:
		

		
			a.   Paragraph 5(b) of the Sponsor Agreement is hereby amended by amending and restating Paragraph 5(b) to read in its entirety as follows:
		

		
			“(b)    On or prior to December 31, 2020 (but not during the continuance of any ordinary share lock-up imposed by underwriters in connection with a Holdings offering applicable to recipients of Merger Shares (as defined below), unless such a lock-up is in existence on December 31, 2020), Holdings shall allot and issue to such Persons as are designated pursuant to this paragraph 5(b) 7,000,000 newly-issued ordinary shares of Holdings (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like, the “Merger Shares”), which Merger Shares shall be issued for no additional consideration and in accordance with all applicable Laws, and such Merger Shares shall be issued, credited as fully paid-up.  The Merger Shares shall be issued to Persons and in amounts designated in a written notice to Holdings given after the date hereof by Jerre Stead and Michael Klein (or, in the event of the death or incapacity of either, by his respective successor to such designation right, the identity of whom shall have been notified to Holdings in writing by the other).  For avoidance of doubt, the Merger Shares are not Locked-up Holdings Securities and are not subject to the Founder Shares Lock-up Period.”
		

		
			b.   All references to “Sweetener Shares” in the Sponsor Agreement shall be replaced with “Merger Shares”.
		

		
			c.   The Sponsor Agreement shall hereby be deemed amended in all other respects necessary to permit the resale of Merger Shares by the holders thereof, including, but not limited to, the offer and sale of such Merger Shares in any Registered Offering, subject to the terms and conditions of the Registration Rights Agreement, to the extent applicable.
		

		
			Section 2.  Interpretation.  Except as explicitly amended on March 29, 2019, September 3, 2019 and hereby, the Sponsor Agreement shall continue, without amendment, in full force and effect from and after the date hereof.  On and after the date hereof, whenever the Sponsor Agreement is referred to in any agreements, documents, or instruments, such reference shall be deemed to be to the Sponsor Agreement as amended on March 29, 2019 and September 3, 2019 and as further amended by this Agreement.
		

		
			Section 3.  Representations and Warranties.  Each of the Company and Holdings represents and warrants, as of the date hereof:
		

		
			a.   it is validly existing and (if applicable) in good standing under the laws of the jurisdiction of its organization, and this Agreement is a legal, valid, and binding obligation of such party, enforceable against it in accordance with its terms, except as enforcement may be
		

		
			
		

		
			

		 

		

			2

		

		

		
			limited by applicable laws relating to or limiting creditors’ rights generally or by equitable principles relating to enforceability;
		

		
			b.   the entry into of, and the performance by it of the transactions contemplated by, this Agreement do not, and will not, conflict in any material respect with any law or regulation applicable to it or with any of its articles of association, memorandum of association or other constitutional documents; and
		

		
			c.   except as expressly provided in this Agreement, it has all requisite corporate or other power and authority to enter into, execute, and deliver this Agreement and to perform its respective obligations under this Agreement.
		

		
			Section 4.  Specific Performance.  The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached, and that money damages or legal remedies would not be an adequate remedy for any such damages.  Therefore, it is accordingly agreed that each party shall be entitled to enforce specifically the terms and provisions of this Agreement, or to enforce compliance with, the covenants and obligations of the other party, in any court of competent jurisdiction.  Any person seeking an injunction, a decree or order of specific performance shall not be required to provide any bond or other security in connection therewith and any such remedy shall be in addition to, and not in substitution for, any other remedy to which such party is entitled at law or in equity.
		

		
			Section 5.  Miscellaneous.  Sections 12 (Entire Agreement; Amendments), 13 (Assignment), 15 (Counterparts), 16 (Severability), 17 (Governing Law; Venue; Waiver of Jury Trial), and 18 (Notices) of the Sponsor Agreement are hereby incorporated into this Agreement by reference as if set forth in full herein, mutatis mutandis, and shall apply in all respects to this Agreement.
		

		
			[Signature page follows.]
		

		
			 
		

		
			

		 

		

			3

		

		

		
			Please signify your agreement with the foregoing Agreement by signing where indicated below.
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Sincerely,

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						CLARIVATE PLC

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						/s/ Jerre L. Stead

				
	
					
						 

					
					
						Name:

					
					
						Jerre L. Stead

				
	
					
						 

					
					
						Title:

					
					
						Chief Executive Officer

				
	
					
						 

					
					
						 

				
	
					
						ACCEPTED AND AGREED

					
					
						 

				
	
					
						as of the date first written above:

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						CAMELOT HOLDINGS (JERSEY) LIMITED

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Stephen Hartman

					
					
						 

				
	
					
						Name:

					
					
						Stephen Hartman

					
					
						 

				
	
					
						Title:

					
					
						Director

					
					
						 

				

		
			 
		

		 

		

			[Signature Page to Amendment to Sponsor Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]